In a series of studies, Varenzin-CA1 was shown to have a reasonable expectation of efficacy in managing anemia in CKD cats. By day 28, 50% of cats given Varenzin-CA1 had increased their red blood ...

(RTTNews) - The U.S. Food and Drug Administration conditionally approved Elanco US Inc.'s Varenzin-CA1 (molidustat oral suspension) for treating anemia in cats with chronic kidney disease or CKD.

Varenzin-CA1 is indicated for the control of nonregenerative anemia associated with chronic kidney disease (CKD) in cats. Varenzin-CA1 Important Safety Information For oral use in cats only.